The Rise of At-Home Ketamine Treatment Companies

A New Industry Takes Shape

At-home ketamine treatment companies have emerged as one of the fastest-growing segments of the mental health industry. These direct-to-consumer services — typically operating through telehealth platforms — offer patients the ability to receive prescribed ketamine in their homes, bypassing the need for costly in-clinic infusions. The model has attracted significant venture capital funding, media attention, and both patient enthusiasm and regulatory scrutiny.

The rapid expansion of this sector reflects the convergence of several forces: the growing evidence base for ketamine as a psychiatric treatment, the normalization of telehealth during and after the COVID-19 pandemic, the high cost and limited geographic availability of in-clinic ketamine infusions, and investor interest in mental health innovation.

The Business Model

How At-Home Ketamine Services Typically Work

Most at-home ketamine companies follow a similar operational structure:

1. Online intake: Patients complete a questionnaire about their psychiatric history, medical conditions, and treatment goals
2. Telehealth evaluation: A licensed clinician (psychiatrist, physician, nurse practitioner, or physician assistant) conducts a video or phone evaluation
3. Prescription: If the patient is deemed appropriate, the clinician prescribes compounded ketamine — usually sublingual troches or rapid dissolve tablets
4. Pharmacy fulfillment: A partnering compounding pharmacy prepares and ships the medication to the patient
5. Treatment guidance: Patients receive instructions for at-home sessions, including dosing, timing, and safety protocols
6. Follow-up: Periodic check-in appointments (usually via telehealth) to assess response and adjust treatment

Pricing Models

Most services operate on a subscription or bundled pricing model:

• Monthly subscriptions: Typically $150-$500 per month, covering medication, shipping, and a set number of clinician appointments
• Per-session pricing: Some services charge per treatment session or per prescription fill
• Bundled packages: Multi-month packages that include initial evaluation, medication, and follow-up visits at a reduced per-month cost

These prices are generally lower than in-clinic IV infusions, which has been a primary driver of patient adoption.

Major Players in the Market

The at-home ketamine market includes both venture-backed startups and more established telehealth platforms that have added ketamine to their service offerings. While specific companies rise and fall in this rapidly evolving market, the industry has generally consisted of:

• Dedicated ketamine telehealth companies: Built specifically around ketamine prescribing, often with extensive educational content and patient support resources
• Broader telehealth platforms: Established telehealth services that have added ketamine as one of many available treatments
• Hybrid models: Companies that offer both in-clinic and at-home treatment options, allowing patients to start in-clinic and transition to at-home maintenance

Clinical Quality: A Spectrum

The clinical quality of at-home ketamine services varies significantly across providers. Key differentiators include:

Higher-Quality Indicators

• Thorough initial evaluation: Comprehensive psychiatric and medical assessment, including review of prior treatment trials, medical history, and contraindication screening
• Experienced clinicians: Evaluations and prescriptions managed by board-certified psychiatrists or other experienced mental health professionals
• Appropriate exclusion criteria: Clear policies excluding patients with contraindications (uncontrolled hypertension, psychotic disorders, active substance abuse)
• Treatment sitter requirement: Mandatory requirement for a sober adult to be present during treatment sessions
• Structured follow-up: Regular, substantive follow-up appointments to assess treatment response and adjust the plan
• Integration with existing care: Communication with the patient's existing therapist or psychiatrist
• Outcome measurement: Use of standardized symptom scales to track treatment response

Lower-Quality Indicators

• Brief, superficial evaluations: Cursory assessments that do not adequately screen for contraindications
• High patient-to-clinician ratios: Clinicians managing large patient panels with minimal individualized attention
• Weak follow-up: Infrequent or perfunctory check-in appointments
• No treatment sitter requirement: Allowing patients to take ketamine alone
• Aggressive marketing: Promotional messaging that overstates benefits, minimizes risks, or guarantees outcomes
• One-size-fits-all dosing: Limited individualization of dosing based on patient response and characteristics

Safety Concerns

FDA Warnings

In 2023, the FDA issued a safety communication regarding compounded ketamine products, stating that these products are not FDA-approved and have not been evaluated for safety, effectiveness, or quality. The communication specifically highlighted risks associated with at-home use, including:

• Potential for serious adverse events without adequate medical supervision
• Variable potency of compounded products
• Risk of medication misuse or diversion

Reports of Adverse Events

Media reports and regulatory filings have documented cases of adverse events associated with at-home ketamine use, including falls, cardiovascular events, and psychological distress. In rare but publicized cases, patient deaths have occurred in the context of at-home ketamine use, though determining whether ketamine was a direct cause versus a contributing factor is often difficult in these cases.

The Supervision Gap

Perhaps the most fundamental concern is the supervision gap between in-clinic and at-home treatment. In a clinical setting, trained staff monitor vital signs, observe the patient throughout the treatment, and can intervene immediately if problems arise. At home, the patient is typically accompanied only by a lay treatment sitter (or, in some cases, no one). This gap becomes more significant for patients who are new to ketamine, who have cardiovascular risk factors, or who experience unexpected psychological reactions.

The Regulatory Response

The growth of at-home ketamine companies has prompted regulatory responses at both the state and federal levels:

• Several states have enacted or proposed legislation specifically addressing telehealth prescribing of ketamine for at-home use
• The DEA's proposed rules on telehealth prescribing of controlled substances would affect the at-home ketamine industry significantly
• State medical boards have issued guidance on standards of care for ketamine prescribing via telehealth
• Some states now require an in-person evaluation before a ketamine prescription can be issued, even if subsequent follow-up occurs via telehealth

The Patient Perspective

Advantages for Patients

At-home ketamine services have expanded access for patients who might not otherwise receive treatment:

• Geographic access: Patients in rural areas or regions without ketamine clinics can access treatment
• Cost: Substantially lower than in-clinic IV infusions for many patients
• Convenience: Treatment at home eliminates travel time, transportation arrangements, and time away from work or family
• Privacy: Some patients prefer the privacy of home treatment over visiting a clinic
• Comfort: The familiar home environment can reduce anxiety associated with treatment

Disadvantages for Patients

• Lower clinical oversight: Less monitoring and immediate support compared to in-clinic treatment
• Lower bioavailability: Sublingual formulations deliver less ketamine to the bloodstream per dose than IV or IM routes
• Variable quality: Difficulty assessing the quality of the service before enrolling
• Potential for isolation: At-home treatment may not provide the therapeutic relationship and clinical support that some patients benefit from
• Regulatory uncertainty: Changing telehealth ketamine regulations could disrupt access to ongoing treatment

Evaluating At-Home Ketamine Services

Patients considering at-home ketamine therapy should evaluate potential providers carefully:

• Research the credentials of the clinicians involved
• Understand the screening and evaluation process
• Ask about follow-up frequency and format
• Confirm that a treatment sitter is required
• Read reviews and seek referrals from trusted healthcare providers
• Understand the company's policies on dose adjustments, adverse events, and treatment discontinuation
• Verify that the compounding pharmacy used meets USP standards

The Future of the Industry

The at-home ketamine industry is at an inflection point. Its future will be shaped by regulatory developments, clinical evidence, patient demand, and the industry's own willingness to adopt and enforce rigorous safety and quality standards. Companies that prioritize clinical quality and patient safety are most likely to survive and thrive in an increasingly regulated environment, while those that cut corners may face regulatory action, legal liability, or loss of public trust.

Note: This article is for educational purposes only and does not constitute an endorsement. For guidance on evaluating providers, see how to find a qualified ketamine provider and clinic vs at-home treatment options or recommendation of any specific at-home ketamine service. Patients should consult with a qualified healthcare provider before initiating any ketamine treatment.

References

• FDA: Drug Information — FDA resource on drug safety, including communications on compounded ketamine products for at-home use
• StatPearls: Ketamine — Clinical reference covering ketamine safety standards and monitoring requirements relevant to at-home treatment
• Ketamine Pharmacology: An Update — NIH review of ketamine pharmacology including bioavailability differences between clinical and at-home formulations
• NIMH: Depression — National Institute of Mental Health information on depression treatment access and evidence-based approaches